Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats

Author: Xueru HE ¹ ; Yuhao FU ¹ ; Xuejiao XUN ¹ ; Xueru HE ² ; Ying LI ² ; Yinling MA ² ; Yuhao FU ² ; Xuejiao XUN ² ; Zhanjun DONG ²
Author Information

1. Graduate School, Hebei Medical University
2. Department of Pharmacy, Hebei Provincial People's Hospital
Publication Type:Journal Article
Keywords: dapagliflozin; drug interactions; pharmacokinetics; sorafenib; UPLC/MS/MS
From: Chinese Journal of Clinical Pharmacology and Therapeutics 2023;28(5):498-507
CountryChina
Language:Chinese
Abstract: AIM: To explore the pharmacokinetic interactions between sorafenib and dapagliflozin in rats and to provide some theoretical basis for the rational clinical use of the two drugs. METHODS: An ultra -performance liquid chromatography-tandem mass spectrometry (UPLC / MS / MS) method was developed for the simultaneous determination of sorafenib and dapagliflozin. Male SD rats were randomly divided into 5 groups (6 rats in each group), including 100 mg / kg sorafenib group, 0.5 mg / kg dapagliflozin group, 1 mg / kg dapagliflozin group, and 100 mg/kg sorafenib combined with 0.5 mg/kg dapagliflozin group and 100 mg/kg sorafenib combined with 1 mg / kg dapagliflozin group, for sorafenib and dapagliflozin drug interaction study. All samples were analyzed using a validated UPLC/ MS/MS method, and the main pharmacokinetic parameters were calculated by compartment model. RESULTS: 1 mg/kg dapagliflozin increased the C